Inflammatory bowel disease (IBD) is a chronic disorder involving mainly the intestinal tract,
but possibly other gastrointestinal and extraintestinal organs. Although etiology is still …

Background & Aims Safety issues are a major concern for patients considering treatments
for inflammatory bowel disease (IBD). We performed a systematic review and meta-analysis …

The management of inflammatory bowel disease represents a key component of clinical
practice for members of the British Society of Gastroenterology (BSG). There has been …

Background Infliximab, a chimeric monoclonal antibody directed against tumor necrosis
factor α, is an established treatment for Crohn's disease but not ulcerative colitis. Methods …

OBJECTIVES: Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory disorders
of the gastrointestinal tract of unknown etiology. Evidence for treatment of the condition with …

Background Ciclosporin and infliximab are potential rescue treatments to avoid colectomy in
patients with acute severe ulcerative colitis refractory to intravenous corticosteroids. We …

Background & Aims: Despite treatment with corticosteroids, severe to moderately severe
attacks of ulcerative colitis have a high colectomy rate. We intended to find a rescue therapy …

OBJECTIVES: Several anti-tumor necrosis factor-α (TNFα) antibodies have demonstrated
efficacy in Crohn's disease (CD) and ulcerative colitis (UC). These drugs carry the …

Background and Aims: Antibodies to infliximab reduce serum infliximab with loss of clinical
benefit, but undetectable trough serum concentrations of infliximab may occur without …

S3 Evidence-Based Systematic Review on Medical Therapies for IBD also has a high
incidence in New Zealand, suggesting that the disease may get more common the further …